P reeclampsia, a complication of pregnancy, occurs in 5% to 8% of pregnancy. Preeclampsia is characterized by hypertension and proteinuria at ≥20 weeks of gestation 1 and associated with iatrogenic preterm delivery, intrauterine growth restriction, placental abruption, and perinatal mortality. Patients with preeclampsia have increased maternal morbidity and mortality rates.
ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 repeats, member 13), a member of the ADAMTS family, plays an important role in regulating hemostasis and thrombosis by cleaving VWF (von Willebrand factor) under shear.
12 ADAMTS13 deficiency is associated with thrombotic thrombocytopenic purpura. Hepatic stellate cells, [13] [14] [15] endothelial cells, 16, 17 megakaryocytes and platelets, 18 renal tubular epithelial cells, glomerular endothelial cells, and glomerular podocytes 19 are shown to produce ADAMTS13 at various levels. ADAMTS13 mRNA was detected in human placentae, 20, 21 but the expression of the protein in the placenta or any specific cell in the placenta has not been investigated. Here, we determined the biosynthesis and secretion of ADAMTS13 in placentae and potential functions of ADAMTS13 in angiogenesis, development of placental tissue, and its association with preeclampsia.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Characteristics of Patients
The baseline characteristics of the study groups are presented in the Table. Controls are matched with severe preeclampsia cases for maternal age, incidence of nulliparity, and gestational age at delivery. As expected, mean birth weight was significantly lower in the severe preeclampsia group, while incidence of fetal growth restriction was obviously higher in the severe preeclampsia group.
ADAMTS13 Is Expressed in Placenta
ADAMTS13 mRNA was detected by a real-time polymerase chain reaction analysis in placentae throughout pregnancy. The placental ADAMTS13 mRNA levels were highest during the first trimester and reduced during the second and third trimesters ( Figure 1A ). The specificity of ADAMTS13 mRNA amplification was demonstrated by the lack of amplification in blank Chinese hamster ovary (CHO) cells and the positive amplification in human liver tissues that are known to express ADAMTS13 mRNA ( Figure 1A ).
14 GAPDH was used to normalize total RNA added during the amplification. The results were expressed as the ratio of ADAMTS13 to GAPDH ( Figure 1A ). Immunoblots using a polyclonal anti-ADAMTS13 IgG demonstrated 120 and 190 kDa protein bands in the placental lysates ( Figure 1B and 1C ) and in the conditioned medium of cultured placental tissues ( Figure 1D ). Consistent with the dynamic changes of mRNA, ADAMTS13 protein was also at the highest levels in placentae during the first trimester and decreased during the second and third trimesters. A positive control consisted of a recombinant full-length ADAMTS13 ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 repeats, member 13) expression in human placenta. A, Real-time polymerase chain reaction (PCR) detected the relative abundance of ADAMTS13 mRNA/GAPDH in human placental villous tissues from first (1st; n=10), second (2nd; n=3), and third (3rd; n=10) trimester of pregnancy. Human liver expressing normal ADAMTS13 mRNA (Liver) was used as a positive control, and blank Chinese hamster ovary (CHO) cell mRNA was used as a negative control. B and C, ADAMTS13 protein in the placental villous tissue lysate by Western blotting with a rabbit anti-ADAMTS13 IgG. D and E, ADAMTS13 protein and activity detected by Western blotting and FRETS (fluorescent resonance energy transfers)-VWF73, respectively, in the conditioned medium of placental villous tissues. All results were presented as the mean±SEM. * indicates a P value <0.05. n.s. indicates a P value >0.05.
expressed from CHO cells by transient transfection of an ADAMTS13 plasmid. A negative control was the cell lysate of untransfected CHO cells, showing no detectable bands (data not shown). ADAMTS13 activity was detected in the concentrated conditioned media of placental culture explants from first (mean 6.2%, range 3.9%-9.3%), second (mean 4.1%, range 1.2%-6.2%), and third (mean 3.9%, range 1.1%-6.5%) trimester ( Figure 1E ). Together, our results demonstrate that a full-length and proteolytically active ADAMTS13 protein is synthesized and secreted from placental tissues throughout normal pregnancy.
Localization of ADAMTS13 in Placental Tissues
Immunohistochemistry using the polyclonal anti-ADAMTS13 IgG demonstrated that ADAMTS13 protein was expressed in both placental and decidual tissues throughout the gestation. Anti-cytokeratin 7, anti-human leukocyte antigen-G, and anti-CD34 marked the cytotrophoblasts (or syncytiotrophoblasts), extravillous trophoblasts, and villous core fetal blood vessel endothelium, respectively. ADAMTS13-positive staining was observed in the villous cytotrophoblasts and syncytiotrophoblasts (Figure 2Aa through 2Ac) , as well as in the extravillous trophoblasts (Figure 2Ba and 2Bb), which were marked by anti-cytokeratin 7 (Figure 2Ad through 2Af ) and antihuman leukocyte antigen-G (Figure 2Bc and 2Bd) , respectively. ADAMTS13 expression was also detected in fetal blood vessel endothelium marked by anti-CD34 and some stromal cells in the villous core (Figure 2Aa 
ADAMTS13 Expression in the Placentae of Patients With Severe Preeclampsia
To assess if ADAMTS13 expression is affected during placental ischemia, the levels of ADAMTS13 mRNA in placental tissue were determined in patients with severe preeclampsia and normal pregnant controls. As shown, ADAMTS13 mRNA in the placentae of patients with severe preeclampsia was dramatically reduced as compared with that in the healthy controls ( Figure 3A) . Western blotting demonstrated the significantly reduced levels of ADAMTS13 protein in the placental villous tissues in patients with severe preeclampsia compared with those in the controls ( Figure 3B and 3C).
To determine whether the reduction of placental expression of ADAMTS13 was caused by tissue ischemia, we determined the levels of placental ADAMTS13 mRNA and protein under normoxic and hypoxic conditions in culture. The results showed that both ADAMTS13 mRNA and protein in placental villous tissues were significantly reduced after being exposed to 2% O 2 (hypoxic) for 48 hours compared with 21% O 2 (normoxic; Figure 3D through 3F). These results suggest that the reduction of ADAMTS13 synthesis and secretion in the placentae of patients with severe preeclampsia may be associated with hypertension-related placental ischemia and tissue hypoxia.
ADAMTS13 Expression in Placental Trophoblast Cells
To confirm the specific cell types in placental villous tissues that express ADAMTS13, we isolated primary placental trophoblasts using an enzyme digestion technique and HTR-8/ SVNEO cell line for the study. By real-time polymerase chain reaction, Western blotting, and FRETS (fluorescent resonance energy transfers)-VWF73, we were able to detect ADAMTS13 mRNA ( Figure 4A ), protein ( Figure 4B ), and proteolytic activity ( Figure 4C ) in the isolated primary trophoblasts and immortalized trophoblast cell line. Immunofluorescent microscopy using the polyclonal anti-ADAMTS13 IgG demonstrated the positive signal in those cells, which were also positive for anti-cytokeratin 7 IgG, marking the placental trophoblasts ( Figure 4D ). Together, our results indicated that both isolated primary trophoblasts and immortalized trophoblastic cell line produce ADAMTS13 transcripts and functional protein.
ADAMTS13 Promotes Trophoblast Cell Proliferation, Migration, Invasion, and Tube Formation
Previous studies demonstrated that ADAMTS13 might be a proangiogenetic or antiangiogenetic factor depending on its local microenvironment. 22, 23 Placenta is an excellent model tissue to study angiogenesis and cell invasion. 
Discussions
The current study demonstrates that ADAMTS13 mRNA and protein are expressed in human normal placentae and deciduae throughout the pregnancy; in the placenta, ADAMTS13 is mainly expressed in trophoblast and fetal blood vessel endothelium; throughout the pregnancy, human placenta synthesizes and secretes ADAMTS13 protein that is proteolytically active; the placental ADAMTS13 is produced at the highest levels in the first trimester and declines in the second and third trimester of gestation, consistent with the progressive decline in plasma ADAMTS13 antigen during pregnancy. 24 ADAMTS13 synthesis is significantly reduced in placental villous tissues in patients with severe preeclampsia, likely resulting from placental ischemia. This hypothesis is supported by the reduction in ADAMTS13 synthesis after placental explant exposed to A, Relative ratios of ADAMTS13 to β-actin mRNA in patients with severe preeclampsia (PE; n=22) and in normotensive pregnany (control; n=25) placentae. B, ADAMTS13 protein detected by Western blotting in placental villous tissues from patients with severe preeclampsia (n=22) and normotensive pregnancy (n=25). C, Quantification of the relative abundance of ADAMTS13 protein in severe preeclamptic placentae and control placentae is shown. D and E, ADAMTS13 mRNA by real-time polymerase chain reaction (PCR) and ADAMTS13 protein by Western blotting in placental explant cultured under normal and hypoxic conditions. F, Quantification of the immunoreactivity of a full-length ADAMTS13 is shown. All results are presented as the mean±SEM (n=10). * indicates the P value <0.05.
the hypoxic conditions; finally, ADAMTS13 promotes proliferation, migration, invasion, and network formation of trophoblasts, suggesting a role of ADAMTS13 protease in normal pregnancy and a potential involvement in the pathogenesis of pregnancy-associated complications. Several members of ADAMTS family are known to express at low levels in human placentae or uterine tissues. 25 This suggests a potential role of other matrix metalloproteinases in implantation and placentation during human pregnancy. This may also explain why ADAMTS13 null mice are viable and fertile. 26, 27 Such redundancy in gene families is common. [28] [29] [30] Indeed, there is increasing evidence of both redundant and nonredundant roles for distinct ADAMTS subtypes in follicular growth and ovulation and in the development and regression of the corpus luteum in the rodent and bovine ovary. [30] [31] [32] [33] While previous study demonstrated the presence of ADAMTS13 mRNA in placentae, 21 its cellular origin and expression levels, as well as biological functions, are not known. Here, we demonstrate that ADAMTS13 mRNA and protein are primarily expressed in the trophoblasts and fetal blood vessel endothelium of human placentae; some stromal cells were also positive for ADAMTS13 protein, likely because of the release of ADAMTS13 into the local tissue environment or potential nonspecific binding of the polyclonal anti-ADAMTS13 antibody.
Previous studies demonstrated that maternal plasma levels of ADAMTS13 activity decrease progressively to 23% of normal in the third trimester. 24 Plasma ADAMTS13 activity begins to decrease at 12 to 16 gestational weeks. 34 Our results suggest that ADAMTS13 produced in placental trophoblasts and endothelium may contribute in part to the levels of maternal plasma ADAMTS13 activity during pregnancy in addition to the potential role in maintenance of local environment. Therefore, the change in maternal plasma ADAMTS13 activity or antigen may reflect the health conditions of placental trophoblasts and villous endothelium during normal and abnormal pregnancy.
ADAMTS13 may play a role in pathophysiology of preeclampsia. Aref and Goda 35 reported a significant reduction of plasma ADAMTS13 activity and increase of plasma VWF in women who were pregnant compared with those who were not. In addition, Stepanian et al 36 demonstrated an association between low ADAMTS13 activity and preeclampsia, independently of VWF. The decrease in plasma ADAMTS13 activity may be related to placental inflammation. 36 In our study, we demonstrated the dramatically reduced levels of placental expression of ADAMTS13 mRNA and protein in patients with severe preeclampsia. This may explain why maternal plasma ADAMTS13 levels are significantly reduced in patients with preeclampsia. The imbalance between ADAMTS13 and VWF during normal pregnancy and preeclampsia may possess a risk for thrombosis in the intervillous and spiral vessel of placentae, which affects uteroplacental circulation and fetal distress. Consequently, placental ischemia and hypoxia may lead to further decline of local synthesis of ADAMTS13 in the placental villous tissues. This vicious cycle may be associated with the pathogenesis and outcome of preeclampsia.
In addition to the well-established role of ADAMTS13 in hemostasis, ADAMTS13 may involve in inflammation, angiogenesis, and tissue remodeling. VWF is upregulated in the microvascular endothelial cells in the area of necrosis and fiber-like structure during liver injury. 37 Therefore, it was speculated that ADAMTS13 release at the time of tissue injury may prevent excessive matrix protein deposition 38 and development of fibrosis in the liver. 39, 40 More recently, Manea et al 19, 41 proposed that ADAMTS13 expressed in tubular cells and podocytes may have other functions, such as tissue remodeling, in addition to simply cleaving VWF. Our results demonstrate the progressive reduction of placental ADAMTS13 levels from first to third trimester, suggesting the participation of ADAMTS13 proteolysis in human embryo implantation.
There has been an increased interest in the role of ADAMTS13 in angiogenesis. The disintegrin or cysteine-rich domains in other ADAMTS family members seem to regulate cell adhesion and migration; 42, 43 the active metalloproteinase domain can degrade extracellular matrix components, leading to the release of growth factors and cytokines, and subsequently promote cell proliferation, migration, and angiogenesis. 38, 44, 45 Conversely, the thrombospondin 1 motif is shown to inhibit angiogenesis by regulating interaction with vascular endothelial growth factor (VEGF) receptors, thereby, regulating VEGF activity. 46, 47 Lee et al 22, 23 reported that ADAMTS13 might exert pro-or antiangiogenic effect depending on the local growth environment. In the absence of excessive VEGF, ADAMTS13 promotes angiogenesis by upregulating VEGF and phosphorylation of VEGFR2 (VEGF receptor-2). In the presence of excessive VEGF, ADAMTS13 seems to inhibit angiogenesis by competing with VEGF for binding to its receptor VEGFR. Our results are consistent with the proangiogenic effect of ADAMTS13 previously found in vitro.
During a normal pregnancy, uterine blood flow increases and enables a perfusion of intervillous space of the placenta and to support fetal growth. The increased blood flow is achieved by physiological transformation of the spiral arteries of the uterus, a process in which trophoblasts invade the arterial wall, destroy the media, and transform the spiral arteries from narrow-diameter to large-diameter vessels. This process enables an adequate perfusion of the placenta. 6 Multiple factors including growth factors, cytokines, and chemokines are involved in this process. In our study, addition of recombinant ADAMTS13 promotes trophoblast cell proliferation, migration, invasion, and tube formation; knockdown of ADAMTS13 expression attenuated the ability of tube formation in HTR-8/SVNEO cells; knockdown of ADAMTS13 in placental explants decreased the migratory and invasive capacity of trophoblast cells. Thus, we propose that the decreased placental ADAMTS13 expression may negatively influence the functions of the trophoblasts, resulting later in the rudimentary remodeling of maternal spiral arteries and abnormal uteroplacental artery blood flow typically associated with preeclampsia.
In summary, our results demonstrate that placental trophoblasts and villous vessel endothelial cells produce a full-length and functional ADAMTS13 protease. Placental expression of ADAMTS13 exhibits a dynamic change during pregnancy, which seems to be inhibited in late pregnancy and in patients with severe preeclampsia, likely because of placental ischemia. Our findings may shed new light on the potential role of ADAMTS13 in placental function, the possible mechanism underlying tissue remodeling during normal pregnancy, and the pathogenesis of placental thrombosis in severe preeclampsia.
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